Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Research and Markets: How to Format Succinct and Comprehensive 510(k)s and PMAs Course: North Carolina, USA, 9th, 10th of July 2015
HeartWare Achieves Primary Endpoint In The ENDURANCE Destination Therapy Clinical Trial
Georgia Pecans Partner with Schwinn Bicycles for Healthy Alliance
Plus, changes at AIM, Fidelity, and Matthews, and more.
Orthopedics remain at risk, but shares are priced below worst-case scenarios.